Abstract
Carcinoid tumors are rare, slow-growing, well-differentiated endocrine tumors and originated from the enterochromaffin cells in the neuroendocrine system. The most common location of carcinoid tumors is the gastrointestinal tract. Carcinoid syndrome occurs in less than 10 % of patients with carcinoid tumors. A number of symptoms including flushing, wheezing, diarrhea, asthma-like symptoms, abdominal pain, diaphoresis, skin lesions, hypotension, and valvular heart disease, especially pulmonary or tricuspid valve involvement, are principal features of the carcinoid syndrome. The signs and symptoms occur due to hormone and peptide and their metabolites secreting from the tumor cells into the bloodstream. Most cases only occur after metastatic spread to the liver.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Oberndorfer S (1907) Karzinoide Tumoren des Dünndarmes. Fr Zeitschrift Pathol 1:426–429
Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934–959
Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072
Rosenbaum FF, Santer DG, Claudon DB (1953) Essential telangiectasia, pulmonic and tricuspid stenosis, and neoplastic liver disease. A possible new clinical syndrome. J Lab Clin Med 42:941–942
Soga J, Yakuwa Y, Osaka M (1999) Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res 18:133–141
Törnebrandt K, Nobin A, Ericsson M, Thomson D (1983) Circulation, respiration and serotonin levels in carcinoid patients during neurolept anaesthesia. Anaesthesia 38:957–967
Marsh HM, Martin JK Jr, Kvols LK et al (1987) Carcinoid crisis during anesthesia: successful treatment with a somatostatin analogue. Anesthesiology 66:89–91
Maton PN (1988) The carcinoid syndrome. JAMA 260:1602–1605
Lundin L, Norheim I, Landelius J et al (1998) Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 77:264–269
Anderson AS, Krauss D, Lang R (1997) Cardiovascular complications of malignant carcinoid disease. Am Heart J 134:693–702
Connolly HM, Nishimura RA, Smith HC et al (1995) Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol 25:410–416
Jensen RT (2012) Endocrine tumors of the gastrointestinal tract and pancreas. In: Longo DL, Fauci AS, Kasper DL (eds) Harrison’s principles of internal medicine, 18th edn. The McGraw-Hill Companies, Inc., NewYork, pp 3056–3071
Warner RRP (1985) Carcinoid tumors. In: Berk JE (ed) Gastroenterology, vol 2, 4th edn. WB Saunders, Philadelphia
Swain CP, Tavill AS, Neale G (1976) Studies of tryptophan and albumin metabolism in a patient with carcinoid syndrome, pellagra, and hypoproteinemia. Gastroenterology 71:484–489
Wang WP, Guo C, Berney DM et al (2010) Primary carcinoid tumors of the testis: a clinicopathologic study of 29 cases. Am J Surg Pathol 34(4):519–524
Sjöblom SM (1988) Clinical presentation and prognosis of gastrointestinal carcinoid tumours. Scand J Gastroenterol 23:779–787
Modlin IM, Gustafsson BI, Moss SF et al (2010) Chromogranin A–biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol 17:2427–2443
Campana D, Nori F, Piscitelli L et al (2007) Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 25:1967–1973
Nehar D, Lombard-Bohas C, Olivieri S et al (2004) Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 60:644–652
Pregun I, Herszényi L, Juhász M et al (2011) Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 84:22–28
Petrou A, Papalambros A, Papaconstantinou I et al (2008) Gastric carcinoid tumor in association with hepatocellular carcinoma: a case report. South Med J 101(11):1170–1172
Pisegna JR, Doppman JL, Norton JA et al (1993) Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome. Dig Dis Sci 38:1318–1328
Dromain C, de Baere T, Baudin E et al (2003) MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 180:121–128
Sippel RS, Chen H (2006) Carcinoid tumors. Surg Oncol Clin N Am 15:463–478
Buchmann I, Henze M, Engelbrecht S et al (2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34:1617–1626
Pavel M, Baudin E, Couvelard A et al (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176
Ramage JK, Ahmed A, Ardill J et al (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61:6–32
Ramage JK, Davies AH, Ardill J (2005) UKNETwork for neuroendocrine tumours: guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54:iv1–iv16
Kvols LK, Moertel CG, O’Connell MJ et al (1986) Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663–666
Rubin J, Ajani J, Schirmer W et al (1999) Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17:600–606
Faiss S, Räth U, Mansmann U et al (1999) Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 60:469–476
Wymenga AN, Eriksson B, Salmela PI et al (1999) Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17:1111
O’Toole D, Ducreux M, Bommelaer G et al (2000) Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88:770–776
Ducreux M, Ruszniewski P, Chayvialle JA et al (2000) The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95:3276–3281
Faiss S, Pape UF, Böhmig M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689–2696
Khan MS, El-Khouly F, Davies P et al (2011) Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther 34:235–242
Oberg K, Kvols L, Caplin M et al (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966–973
Strosberg JR, Fisher GA, Benson AB et al (2013) Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas 42:397–404
Strosberg J, Weber J, Feldman M et al (2013) Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors. Gastrointest Cancer Res 6:81–85
Oberg K, Funa K, Alm G (1983) Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 309:129–133
King J, Quinn R, Glenn DM et al (2008) Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113:921–929
Bushnell DL Jr, O’Dorisio TM, O’Dorisio MS et al (2010) 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28:1652–1659
Woodside KJ, Townsend CM Jr, Mark Evers B (2004) Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg 8:742–756
Warner RR, Mani S, Profeta J, Grunstein E (1994) Octreotide treatment of carcinoid hypertensive crisis. Mt Sinai J Med 61:349–355
Boudreaux JP, Klimstra DS, Hassan MM et al (2010) The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 39:753–766
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kilickap, S., Yalcin, S. (2015). Carcinoid Syndrome. In: Yalcin, S., Öberg, K. (eds) Neuroendocrine Tumours. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45215-8_29
Download citation
DOI: https://doi.org/10.1007/978-3-662-45215-8_29
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-45214-1
Online ISBN: 978-3-662-45215-8
eBook Packages: MedicineMedicine (R0)